Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

ChromX Forms Diagnostic Collaboration with Boehringer Ingelheim for Lung Fibrosis

publication date: Nov 15, 2023

ChromX Health of Guangzhou will collaborate with Germany’s Boehringer Ingelheim to advance research on interstitial lung disease and to develop early diagnostic and intervention devices. ChromX is developing a breath-analyzing device that detects microminiature volatile organic compounds that serve as biomarkers for lung disease screening and diagnosis. BI has a novel drug candidate for idiopathic pulmonary fibrosis in a Phase III clinical trial. Interstitial lung disease (ILD) is an umbrella term used for a large group of diseases that cause fibrosis of the lungs, which can cause breathing difficulties and death. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital